Gene Therapy Shows Promise for Aggressive Lymphoma
By webmd.com
An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy's developers report.
Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif.
These patients had not responded to usual treatments and had no other options, Kite said Tuesday in a news release.
Overall, more than four out of five patients with the blood cancer saw their cancer reduced by more than half for at least part of the study, the company said.
"This seems extraordinary ... extremely encouraging," one cancer specialist, Dr. Roy Herbst, told the Associated Press.
But Herbst, who is chief of medical oncology at Yale Cancer Center in New Haven, Conn., said longer follow-up is needed to see if the benefit continues.
Still, he said, "This certainly is something I would want to have available." Side effects, which had been a concern, seemed manageable in this study, he said.
The therapy -- called CAR-T cell therapy -- enables the patient's own blood cells to kill the cancer cells.
Lymphoma is a general term for cancers that begin in the lymph system. The lymph system is part of the immune system, which helps the body fight disease.
Here's how the treatment works: A patient's blood is filtered so immune cells called T-cells can be altered to contain a cancer-fighting gene. The cells are returned to the patient intravenously, and the cancer-targeting cells then multiply in the patient's body.
The U.S. National Cancer Institute developed the gene approach and licensed it to Kite. Now, Kite and another pharmaceutical giant, Novartis AG, are competing to gain approval of the treatment, according to the AP.
Kite reportedly intends to seek U.S. Food and Drug Administration approval this spring and approval in Europe later this year. It could be the first gene therapy approved in the United States, the news report noted.
Although the therapy appears to benefit a significant number of patients, it is not risk-free. Researchers believe two patients died of treatment-related causes, the AP reported.
Other side effects included anemia or other blood problems that were treated, and neurological problems such as sleepiness, confusion, tremor or difficulty speaking, which typically lasted only a few days, the wire service reported.
Overall, however, the therapy seems safe, according to Dr. Steven Rosenberg, chief of surgery branch at the National Cancer Institute. He was not involved with the study.
"It's a safe treatment, certainly a lot safer than having progressive lymphoma," Rosenberg told the AP. He said he has a patient who was treated this way who is still in remission seven years later.
The cost of such treatment hasn't been reported yet, but immune system therapies tend to be very expensive.
The results are scheduled for presentation at the American Association for Cancer Research conference in April. Until published in a peer-reviewed medical journal, the data and conclusions should be considered preliminary.
Source: http://www.webmd.com/cancer/lymphoma/news/20170228/gene-therapy-shows-promise-for-aggressive-lymphoma
Saturday, May 30, 2026
Methocarbamol (Robaxin) - Muscle Relaxants guide
Methocarbamol treatment decisions focus on short-term spasm relief, sedation control, and safe integration with rehabilitation plan. Drug helps symptoms from acute musculoskeletal injury, but does not replace diagnosis review or functional recovery work. Clinicians choose dose timing based on daytime demands and fall-risk profile. Higher sedative burden may require evening-weighted schedule, while daytime doses may be minimized for patients who drive, operate machinery, or need sustained concentration. Important part of robaxin-methocarbamol treatment decisions is interaction screening. Alcohol, opioids, benzodiazepines, sedating antihistamines, sleep agents, and some antipsychotics can amplify central nervous system depression and increase confusion or respiratory risk. Duration planning matters. Methocarbamol is commonly used for limited acute phase, then tapered as mobility and tissue recovery improve. Persisting severe pain after short trial should trigger reassessment for alternate diagnosis or broader pain strategy. Monitoring should include daytime sedation, dizziness, gait stability, blurred vision, and ability to perform routine tasks safely. Family observations are useful when patient underreports impairment. If side effects are significant, clinicians may adjust timing, reduce dose, or switch medication class. Abrupt self-escalation to chase pain relief is unsafe and rarely effective. Non-drug supports should run in parallel: mobility progression, targeted stretching, posture correction, hydration, and sleep optimization. These interventions reduce recurrence risk and medication reliance. Patients should receive clear stop criteria, including when to seek urgent care for severe weakness, persistent neurologic deficits, confusion, breathing concerns, or falls. For broader comparison of spasm-management options and safer recovery pathways, patients can review muscle relaxants treatment guidance before follow-up visits. Written dose plan with daytime caution notes helps patients avoid work-safety mistakes during first treatment days. Short review interval allows quick adjustment before sedation causes falls or missed work. Function tracking should include sleep quality, walking tolerance, and return-to-task confidence. Clear communication improves adherence. Consistency supports recovery.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.